8-K: Sangamo Therapeutics Delisted from Nasdaq, Sells Assets in Bankruptcy

Sangamo Therapeutics has been delisted from Nasdaq and completed the sale of substantially all its assets, including the ST-920 program, as part of its Chapter 11 bankruptcy proceedings.

Summary

• Sangamo Therapeutics' common stock was suspended from trading on Nasdaq on May 5, 2026, and is now trading on the OTCID Basic Market.
• Nasdaq filed a Form 25 with the SEC to delist the company's shares, effective September 27, 2026.
• The company filed for Chapter 11 bankruptcy on June 23, 2026.
• On September 17, 2026, Sangamo completed the sale of substantially all its assets, primarily related to the ST-920 gene therapy candidate, to PTC Therapeutics.
• The sale includes $111 million in cash at closing and up to $100 million in contingent consideration based on milestones.
• Trading in the company's common stock is highly speculative and poses substantial risks.

Sentiment

Score: 1

Explanation: StockSavvy.ai views this filing as extremely negative due to the company's delisting from Nasdaq, Chapter 11 bankruptcy filing, and the sale of substantially all assets, indicating severe financial distress and a likely loss for common stockholders.

Positives

• Completion of the sale of substantially all assets, providing some cash and potential future payments.
• The sale of the ST-920 program to PTC Therapeutics may allow the asset to continue development.

Negatives

• Delisting from the Nasdaq Capital Market.
• Chapter 11 bankruptcy filing, indicating severe financial distress.
• Sale of substantially all company assets.
• Trading in common stock is highly speculative with substantial risks.
• Trading prices for common stock may bear little or no relationship to recovery in bankruptcy.

Risks

• The Chapter 11 bankruptcy process poses substantial risks to common stockholders.
• The delisting from Nasdaq and trading on the OTC market significantly reduces liquidity and visibility.
• The value of any recovery for common stockholders in the bankruptcy case is uncertain and likely minimal.

Future Outlook

The future outlook for Sangamo Therapeutics as a going concern is extremely bleak, given the sale of substantially all its assets and its Chapter 11 bankruptcy. The company's focus will likely shift to winding down operations and distributing any remaining proceeds to creditors and, if anything is left, to shareholders.

Management Comments

• The Company urges extreme caution with respect to existing and future investments in its common stock.

Industry Context

StockSavvy.ai notes that this filing reflects a severe downturn for Sangamo Therapeutics, a company that was once a leader in gene editing and cell therapy. The Chapter 11 filing and asset sale are indicative of the high-risk, capital-intensive nature of biotechnology, where clinical trial failures, funding challenges, or strategic missteps can lead to such outcomes. The sale of its core assets to PTC Therapeutics suggests that while Sangamo may cease to exist in its current form, the technology may still find a path forward under new ownership.

Comparison to Industry Standards

• Companies in the biotechnology sector often face significant financial challenges due to long development cycles and high R&D costs. However, a complete Chapter 11 filing and sale of substantially all assets, leading to Nasdaq delisting, represents one of the most severe outcomes.
• While many biotech firms undergo restructurings or seek mergers, Sangamo's situation is comparable to companies like AveXis (acquired by Novartis after significant setbacks) or Sarepta Therapeutics (which faced intense scrutiny and clinical trial challenges), though Sangamo's path has led to bankruptcy rather than acquisition at a premium.
• The sale of a gene therapy candidate like ST-920 for $111 million cash plus contingent payments is a significant transaction, but the overall context of bankruptcy diminishes its positive implications for existing shareholders.

Legal Proceedings

• Chapter 11 Bankruptcy Case (Case No. 26-10989) in the United States Bankruptcy Court for the District of Delaware.

Stakeholder Impact

• Shareholders: Trading in common stock is highly speculative and poses substantial risks, with little to no expected recovery.
• Creditors: The bankruptcy process will determine the priority and extent of recovery for creditors.
• Employees: The sale of assets and bankruptcy proceedings likely lead to significant workforce reductions.
• Suppliers: Unsecured suppliers may face challenges in recovering payments owed.

Next Steps

• The delisting from Nasdaq will become effective on September 27, 2026.
• The company will continue to operate as a debtor-in-possession under the jurisdiction of the Bankruptcy Court.
• The company will focus on winding down operations and managing the bankruptcy process.

Key Dates

Recommendation

Given the Chapter 11 bankruptcy filing, delisting from Nasdaq, and the sale of substantially all assets, the common stock is highly speculative and likely worthless. Investors should sell any holdings to avoid further potential losses, as recovery in bankruptcy is improbable for equity holders.

Keywords

Chapter 11, Bankruptcy, Asset Sale, Delisting, Gene Therapy, Fabry Disease, PTC Therapeutics, ST-920